ATE290398T1 - Verwendung von alpha-1 antichymotrypsin zur herstellung von einer zusammensetzung zur behandlung, vorbeugung oder diagnose von schwerheilenden diabätische wunden - Google Patents
Verwendung von alpha-1 antichymotrypsin zur herstellung von einer zusammensetzung zur behandlung, vorbeugung oder diagnose von schwerheilenden diabätische wundenInfo
- Publication number
- ATE290398T1 ATE290398T1 AT02724304T AT02724304T ATE290398T1 AT E290398 T1 ATE290398 T1 AT E290398T1 AT 02724304 T AT02724304 T AT 02724304T AT 02724304 T AT02724304 T AT 02724304T AT E290398 T1 ATE290398 T1 AT E290398T1
- Authority
- AT
- Austria
- Prior art keywords
- antichymotrypsin
- diagnosis
- alpha
- prevention
- treatment
- Prior art date
Links
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 title abstract 2
- 206010052428 Wound Diseases 0.000 title abstract 2
- 208000027418 Wounds and injury Diseases 0.000 title abstract 2
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000035876 healing Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10121255A DE10121255A1 (de) | 2001-04-30 | 2001-04-30 | Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen |
| US32334801P | 2001-09-18 | 2001-09-18 | |
| PCT/EP2002/004757 WO2002088180A2 (en) | 2001-04-30 | 2002-04-30 | Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE290398T1 true ATE290398T1 (de) | 2005-03-15 |
Family
ID=26009207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02724304T ATE290398T1 (de) | 2001-04-30 | 2002-04-30 | Verwendung von alpha-1 antichymotrypsin zur herstellung von einer zusammensetzung zur behandlung, vorbeugung oder diagnose von schwerheilenden diabätische wunden |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP1568376B1 (de) |
| JP (2) | JP4384855B2 (de) |
| AT (1) | ATE290398T1 (de) |
| AU (1) | AU2002254999B2 (de) |
| CA (1) | CA2446197C (de) |
| DK (1) | DK1392354T3 (de) |
| ES (1) | ES2239715T3 (de) |
| WO (1) | WO2002088180A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1415664A1 (de) * | 2002-10-30 | 2004-05-06 | Switch Biotech Aktiengesellschaft | Verwendung von Alpha-1-antichymotrypsin in Kombination mit Alpha-1-antitrypsin zur Behandlung/Vorbeugung von schlecht heilenden arteriellen oder diabetischen Wunden |
| EP1666075A1 (de) | 2004-10-04 | 2006-06-07 | Switch Biotech Aktiengesellschaft | Wundverband zur Freisetzung von Proteaseinhibitoren |
| CA2661332A1 (en) * | 2006-09-01 | 2008-03-13 | American Type Culture Collection | Compositions and methods for diagnosis and treatment of type 2 diabetes |
| EP2957283B1 (de) | 2014-06-19 | 2022-12-21 | Symrise AG | Verfahren zur Identifizierung von Medikamenten zur Beschleunigung der Wundheilung |
| WO2022111793A1 (en) | 2020-11-24 | 2022-06-02 | Symrise Ag | Medicament for accelerated wound healing |
| WO2022161593A1 (en) | 2021-01-26 | 2022-08-04 | Symrise Ag | Medicament for accelerated wound healing |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| US5008242A (en) * | 1986-12-24 | 1991-04-16 | John Lezdey | Treatment of inflammation using 1-antichymotrypsin |
| US5723316A (en) * | 1989-06-23 | 1998-03-03 | Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin analogues having chymase inhibiting activity |
| US5674708A (en) * | 1989-06-23 | 1997-10-07 | Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin analogues having elastase inhibitory activity |
| US5780587A (en) * | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
| EP0546101A1 (de) * | 1990-08-24 | 1993-06-16 | The President And Fellows Of Harvard College | Verfahren zur störung der bildung des alpha-antichymotrypsin-beta-protein-komplexe und synthetische peptide zur verwendung dabei |
| EP0512090B2 (de) * | 1990-10-16 | 2006-11-22 | Sonoran Desert Chemicals LLC | Behandlung von entzündungen |
| US5698765A (en) | 1991-12-02 | 1997-12-16 | The Ontario Cancer Institute | Mouse having a disrupted CD4 gene |
| WO1993018144A1 (en) | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
| US5625122A (en) | 1992-04-24 | 1997-04-29 | The Ontario Cancer Institute | Mouse having a disrupted lck gene |
| US5422244A (en) * | 1992-05-05 | 1995-06-06 | Athena Neurosciences, Inc. | Detection of brain α1-antichymotrypsin |
| JP3741447B2 (ja) | 1992-10-23 | 2006-02-01 | 中外製薬株式会社 | エンドセリン−１遺伝子の機能が欠損したマウス |
| DE19625049A1 (de) | 1996-06-22 | 1998-01-02 | Inst Pflanzengenetik & Kultur | Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält |
-
2002
- 2002-04-30 AU AU2002254999A patent/AU2002254999B2/en not_active Ceased
- 2002-04-30 EP EP05005000A patent/EP1568376B1/de not_active Expired - Lifetime
- 2002-04-30 DK DK02724304T patent/DK1392354T3/da active
- 2002-04-30 WO PCT/EP2002/004757 patent/WO2002088180A2/en active IP Right Grant
- 2002-04-30 JP JP2002585477A patent/JP4384855B2/ja not_active Expired - Fee Related
- 2002-04-30 CA CA2446197A patent/CA2446197C/en not_active Expired - Fee Related
- 2002-04-30 EP EP02724304A patent/EP1392354B1/de not_active Expired - Lifetime
- 2002-04-30 ES ES02724304T patent/ES2239715T3/es not_active Expired - Lifetime
- 2002-04-30 AT AT02724304T patent/ATE290398T1/de active
-
2008
- 2008-04-18 JP JP2008109172A patent/JP2008283966A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP4384855B2 (ja) | 2009-12-16 |
| WO2002088180A3 (en) | 2003-04-24 |
| WO2002088180A2 (en) | 2002-11-07 |
| JP2008283966A (ja) | 2008-11-27 |
| EP1392354B1 (de) | 2005-03-09 |
| ES2239715T3 (es) | 2005-10-01 |
| EP1568376A3 (de) | 2005-10-05 |
| CA2446197A1 (en) | 2002-11-07 |
| JP2005508137A (ja) | 2005-03-31 |
| AU2002254999B2 (en) | 2007-07-26 |
| EP1568376A2 (de) | 2005-08-31 |
| CA2446197C (en) | 2011-12-13 |
| DK1392354T3 (da) | 2005-07-04 |
| EP1568376B1 (de) | 2012-11-21 |
| EP1392354A2 (de) | 2004-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69940888D1 (de) | Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie | |
| HK1091499A1 (en) | Methods for preventing and treating alzheimers disease (ad) (ad) | |
| DE69634726D1 (de) | Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen | |
| DE60333963D1 (de) | Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität | |
| NO1996007I1 (no) | Human koagulasjons faktor VII (FVII) | |
| DE69334246D1 (de) | Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome | |
| DE69022425D1 (de) | Verfahren zur Bestimmung der funktionellen Wirkung von freiem Protein S oder Protein C in einer Plasmaprobe. | |
| ATE209684T1 (de) | Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung | |
| ATE168135T1 (de) | Diagnose von retinoblastoma | |
| ATE242005T1 (de) | P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes | |
| ATE290398T1 (de) | Verwendung von alpha-1 antichymotrypsin zur herstellung von einer zusammensetzung zur behandlung, vorbeugung oder diagnose von schwerheilenden diabätische wunden | |
| DE60045681D1 (de) | Vaskuläre adhesionsmoleküle und modulierung ihrer funktion | |
| WO2000034511A3 (de) | Peptid screening test zum nachweis von ass | |
| DE69233507D1 (de) | Hbgad und higad polypeptide und nukleinsäuren und deren verwendung zur diagnose und behandlung von gad autoantigen assoziierten krankheiten | |
| EP1281763A3 (de) | Early growth response-1 (EGR-1) transkriptions-faktor | |
| ATE450604T1 (de) | Gsk3-polypeptide | |
| EP1114862A3 (de) | Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen | |
| DK70785D0 (da) | Kompres samt fremgangsmaade til dets fremstilling | |
| WO2003072126A3 (de) | Verwendung eines fibroblastenwachstumsfaktor-bindeproteins zur behandlung und diagnose von diabetischen wundheilungsstörungen | |
| ATE395602T1 (de) | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren | |
| ATE432287T1 (de) | Peptidfragmente mit den zelltod verhindernder aktivität | |
| DE69939379D1 (de) | Hemmstoff zur diagnose und behandlung von haemophilia a patienten | |
| DE69903278D1 (de) | Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit | |
| DE60203172D1 (de) | Verwendung von alpha-1 antichymotrypsin zur herstellung von einer zusammensetzung zur behandlung, vorbeugung oder diagnose von schwerheilenden diabätische wunden | |
| WO2002082092A3 (de) | Bestimmung der wirksamen parathormon-aktivität in einer probe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1392354 Country of ref document: EP |